LEO Pharma- UK lays claim to being king of the dermatology drug jungle in the UK. LEO Pharma UK company, which is the British arm of Denmark's LEO Pharma, handles the sales and marketing LEO's dermatological and critical care pharmaceutical products in the UK. LEO Pharma UK also has a growing medical department which conducts clinical studies on behalf of the group. The parent company focuses on topical prescription medications for psoriasis and other dermatological conditions. The group's lead critical care products include anticoagulant heparin (derived from porcine mucosa) and vitamin D.

DPT Laboratories will turn a discovered drug into a developed and commercialized drug. The contract manufacturing and development company makes prescription and over-the-counter drugs with an emphasis on semi-solid and liquid formulations including lotions, gels, aerosol foams, nasal sprays, and creams. It works with both conventional and biopharmaceutical compounds and can manufacture small quantities for pilots and clinical trials, and all the way up to commercial production. DPT is a subsidiary of DFB Pharmaceuticals and has manufacturing facilities in Texas and New Jersey.

Eurand, Inc. company, a subsidiary of Netherlands-based Eurand N.V., develops drug delivery technologies to help drugmakers improve the efficacy of their products. Eurand researches and manufactures drugs marketed in the Americas and Europe, mostly through partnerships with other pharma companies. Eurand's drug delivery systems include Biorise to make certain drugs water soluble; Diffucaps and Minitabs to control the release of drug components as they make their way through the digestive system; and AdvaTab and Liquitard to mask the taste of medicines. The company also conducts research for its parent's own portfolio of drugs under development.

Takeda Cambridge (formerly Paradigm Therapeutics) is researching hundreds of potential drug targets in hopes of finding more effective and faster treatments for central nervous system disorders, endocrinology, urology, chronic pain, and metabolic diseases. The genomics-based drug discovery company, which was spun out of the University of Cambridge, uses several research methods based on genetic models and pharmacology to identify drug targets. Subsidiary Takeda Singapore Pte Ltd conducts research in Asia. The company was acquired by Takeda Pharmaceutical in 2007.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

Advanced Vision Research, Inc. company makes TheraTears, a line of over-the-counter eye drops developed to treat dry eye, a condition caused by aging, contact lens wear, sun, or wind. TheraTears are designed to imitate human tears, keeping eyes moist and allowing the surface of the eye to absorb oxygen and other needed nutrients. Other products include a TheraTears version for contact lens-wearers, an Omega-3-infused version to promote eye health, and an eyelid cleanser. Advanced Vision's products are made by Akorn's contract manufacturing unit and are sold through global retail outlets. TheraTears was developed by the late founder and former CEO Jeffrey Gilbard.

Biovitrum company makes pharmaceuticals that treat hemophilia and autoimmune diseases like rheumatoid arthritis, scleroderma (hardening of the skin), and others. Its available products include arthritis drug Kineret and cancer side-effect drug Kepivance. Biovitrum company also has drugs for inflammatory diseases and absorption disorders in development in its pipeline. Biovitrum distributes its products to Europe, Australia, and the US through partnerships with pharmaceutical giants like Pfizer and Amgen.

PetMed Express, Inc. was founded in 1996 and is headquartered in Pompano Beach, Florida. PetMed Express, Inc. (PetMed) and its subsidiaries, doing business as 1-800-PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs, cats, and horses direct to the consumer. The Company markets its products through national television, online, and direct mail/print advertising campaigns. PetMed offers a selection of products for dogs, cats, and horses. As of March 31, 2009, its product line contains approximately 750 stock keeping units (skus). These products include brands of medication, such as Frontline Plus, K9 Advantix, Advantage, Heartgard Plus, Sentinel, Interceptor, Program, Revolution, Deramaxx and Rimadyl.

Micromet, Inc. (Micromet) is a biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. Four of the Company's antibodies are in clinical trials, while the remainder of its product pipeline is in pre-clinical development. The Company’s BiTE antibody blinatumomab, known as MT103, is being evaluated in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia (ALL), and in a phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). A second BiTE antibody, MT110, is being tested in a phase I clinical trial for the treatment of patients with solid tumors. MT110 binds to the epithelial cell adhesion molecule (EpCAM), which is over-expressed in many solid tumors.

Aspreva Pharmaceuticals believes that bad aim can be a good thing when treating diseases. This company conducts clinical trials to find new uses for approved drugs. As a result, partners team up with Aspreva to gain incremental revenue from the commercialization of the new version of the drug. Working in collaboration with Roche, Aspreva conducts clinical trials to investigate the use of Roche's CellCept (indicated for prevention of rejection in organ transplant patients) to treat autoimmune diseases including lupus nephritis and pemphigus vulgaris. Aspreva is a subsidiary of Swiss pharmaceutical firm Galenica Group.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.